Skip to content
The Nexus
DossierENTITY

treatment-resistant depression

Coverage of treatment-resistant depression in the Nexus archive.

Earliest in view: Apr 24 · 18:06 UTCMost recent: May 29 · 11:00 UTC
Co-mentioned in this coverage
major depressive disordertopic2University of Connecticut School of Medicineorganization1ketaminetopic1Taeho Greg Rheeperson1JAMA Psychiatryorganization1antidepressantstopic1Food and Drug Administrationorganization1psilocybintopic1post-traumatic stress disordertopic1Trump administrationorganization1
Recent coverage
  • HEALTHMay 29 · 11:00 UTCFOX NEWS
    Single infusion of controversial drug changed severe depression symptoms within hours, study finds

    A study reviewed 26 clinical trials involving over 1,100 patients, finding that a single ketamine infusion significantly reduced severe depression symptoms within four hours and lowered suicidal thoughts within 24 hours. The analysis suggests ketamine may offer rapid relief for treatment-resistant depression, though it carries risks like dissociation and nausea.

  • HEALTHApr 24 · 18:06 UTCTHE HILL
    FDA moves to fast-track review of 3 psychedelic drug studies

    The FDA granted fast-track review to three companies studying psychedelic therapies for depression and PTSD, with two focusing on psilocybin for treatment-resistant depression and major depressive disorder. This move aligns with the Trump administration's push for potential approval of psychedelic treatments.

treatment-resistant depression · Dossier · The Nexus